Sound waves and genes offer new path to control seizures without surgery

Bioengineers at Rice University have figured out how to quiet seizure activity in the brain using something that sounds like science fiction: ultrasound waves, genetic engineering, and a pill you can take at home.

The breakthrough matters because seizures often stem from hyperactive neurons clustered in one specific area — usually the hippocampus — but current treatments either affect the whole brain or require surgical implants. This new approach, tested in animal models, targets only the problem zone and leaves everything else alone.

How it actually works

The method, called acoustically targeted chemogenetics or ATAC, starts with an injection of microscopic gas bubbles into the bloodstream. When focused ultrasound beams zero in on the hippocampus, the bubbles gently nudge blood vessel walls, creating tiny temporary openings in the blood-brain barrier — the brain's normally impenetrable security system. These pores close naturally within hours, but they're large enough to let gene therapy vectors slip through and deliver their cargo: genetic instructions for what researchers call a molecular "dimmer switch."

Once installed in the neurons, this dimmer switch makes brain cells responsive to a specific drug. Take the drug, and overactive neurons quiet down. Skip it, and everything returns to normal. No permanent implant. No surgery. No constant stimulation affecting the entire brain.

"By precisely targeting the hippocampus, we can dampen overactivity where it matters and leave the rest of the brain untouched," said Honghao Li, the doctoral student who led the study.

What makes this genuinely significant is that both focused ultrasound and viral vector gene delivery are already in clinical trials for other conditions. The Rice team, led by assistant professor Jerzy Szablowski, isn't inventing entirely new technology — they're combining existing tools in a smarter way. That's the kind of innovation that can move from lab to clinic faster than breakthroughs that require building everything from scratch.

The team has also developed a complementary technique called REMIS that works in reverse: it lets proteins from specific brain regions leak into the bloodstream so clinicians can measure what's happening in the exact circuit they're targeting. Together, these tools create something like a complete feedback loop — deliver therapy, control which neurons respond, then measure the results.

The ultimate vision is a flexible platform that can reach any brain region, deliver genetic material with precision, and let patients control it with a simple dose. For the estimated 50 million people worldwide with epilepsy, and for the growing list of neurological conditions driven by overactive cells in specific locations, that's a meaningful shift from "we have to operate" to "we can try this first."